Publications by authors named "Meletios Dimopoulos"

Claim this Profile
P
Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy.
Heinz Ludwig, Meletios Athanasios Dimopoulos, Evangelos Terpos, Sarah Bernhard, Foteini Theodorakakou

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center Experience.
Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Charalampos Filippatos, Sotirios Maganas, Despina Fotiou, Meletios A Dimopoulos

Clin Lymphoma Myeloma Leuk· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study.
Ramón García-Sanz, Roger G Owen, Wojciech Jurczak, Meletios A Dimopoulos, Helen McCarthy

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenström macroglobulinemia.
Tina Bagratuni, Ourania Theologi, Christos Vlachos, Ioannis Kollias, Kylee Maclachlan, Meletios A Dimopoulos

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current experiences with teclistamab in patients with multiple myeloma and renal impairment.
Meletios A Dimopoulos, Yael C Cohen, Aurore Perrot, Matthew J Pianko, Edward A Faber

Expert Rev Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.
Nizar J Bahlis, Jeffrey Zonder, Lionel Karlin, Torben Plesner, Laura Paris, Meletios A Dimopoulos

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone disease burden does not impact overall survival in newly diagnosed patients with multiple myeloma - a single center, retrospective imaging analysis on 119 patients.
Evangelos Terpos, Vassilis Koutoulidis, Ioannis Ntanasis-Stathopoulos, Stylianos Mavropoulos-Papoudas, Maria Douka, Meletios A Dimopoulos

J Bone Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma.
Meletios A Dimopoulos, Sagar Lonial, Wee-Joo Chng, Shinsuke Iida, María-Victoria Mateos

Blood Cancer J· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma.
Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panos Malandrakis, Despina Fotiou, Meletios A Dimopoulos

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Luciano J Costa, Nizar J Bahlis, Aurore Perrot, Ajay K Nooka, Jin Lu, Meletios A Dimopoulos

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.
Rakesh Popat, Meral Beksac, Meletios A Dimopoulos, Moshe E Gatt, Francesca Gay

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs.
Tomas Jelinek, David Žihala, Aintzane Zabaleta, Ioannis V Kostopoulos, Ondrej Soucek, Meletios A Dimopoulos

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.
María-Victoria Mateos, Suzanne Trudel, Hang Quach, Paweł Robak, Meral Beksac, Meletios Athanasios Dimopoulos

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.
Meletios A Dimopoulos, Meral Beksac, Ludek Pour, Sosana Delimpasi, Vladimir Vorobyev

Lancet Haematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases.
Maroulio Pertesi, Delphine Demangel, Abhishek Niroula, Emeline Perrial, Maria Laura Mahecha Escobar, Meletios A Dimopoulos

Leukemia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network.
Niels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, Maria-Victoria Mateos, Meletios A Dimopoulos

Hemasphere· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of 15-Year Progression-Free Survival in Multiple Myeloma; Real-World Data From a Single Institution.
Meletios A Dimopoulos, Ioannis Ntanasis-Stathopoulos, Despina Fotiou, Foteini Theodorakakou, Eirini Solia

Am J Hematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events.
Evangelos Terpos, Suzanne Trudel, María-Victoria Mateos, Nicolás Alejandre, Kathryn Colby, Meletios A Dimopoulos

Am J Hematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphadenopathy is an independent prognostic factor for patients with Waldenström macroglobulinaemia.
Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Despina Fotiou, Vassiliki Labropoulou, Nikolaos Giannakoulas, Meletios Athanasios Dimopoulos

Br J Haematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum Proteomics of Ribociclib-Mediated Cardiovascular Toxicity: An Exploratory Case-Control Study.
Oraianthi Fiste, Martina Samiotaki, Efstathios Manios, Chrysanthi Trika, Christine Ivy Liacos, Meletios Athanasios Dimopoulos

Proteomics Clin Appl· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
Vania Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, Meletios A Dimopoulos

Lancet Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unpublished overall survival confounders in immunomodulatory agent registrational trials - Authors' reply.
Jesus San-Miguel, Paul Richardson, Meletios A Dimopoulos

Lancet Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab for High-Risk Smoldering Multiple Myeloma. Reply.
Meletios A Dimopoulos, Peter M Voorhees, S Vincent Rajkumar

N Engl J Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteomic Analysis of Bone Marrow CD138+ Cells to Identify Proteins Associated With the Response of Multiple Myeloma Patients to Commonly Used Therapeutic Regimens.
Foteini Paradeisi, Aggeliki Tserga, Vasiliki Lygirou, Manousos Makridakis, Rafael Stroggilos, Meletios A Dimopoulos

Proteomics· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network.
Grigoris Gerotziafas, Despina Fotiou, Inger Nijhof, Cihan Ay, Ramon Lecumberri, Meletios A Dimopoulos

Hemasphere· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis